Company Overview
BrightPath is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. In addition to cancer peptide vaccines currently in clinical trials in Japan and the United States (ITK-1, GRN-1201, and GRN-1301), BrightPath is actively involved in developing cell therapies, immunomodulatory antibodies and new drugs targeted at cancer-specific neoantigens.